Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Payables (2022 - 2025)

Historic Payables for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • Gossamer Bio's Payables fell 6349.36% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 6349.36%. This contributed to the annual value of $2.3 million for FY2024, which is 5803.47% down from last year.
  • As of Q3 2025, Gossamer Bio's Payables stood at $1.1 million, which was down 6349.36% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Gossamer Bio's Payables peaked at $5.5 million during Q4 2023, and registered a low of $363000.0 during Q3 2022.
  • For the 4-year period, Gossamer Bio's Payables averaged around $2.2 million, with its median value being $2.2 million (2023).
  • As far as peak fluctuations go, Gossamer Bio's Payables skyrocketed by 36131.76% in 2023, and later crashed by 6349.36% in 2025.
  • Gossamer Bio's Payables (Quarter) stood at $1.5 million in 2022, then skyrocketed by 278.75% to $5.5 million in 2023, then tumbled by 58.03% to $2.3 million in 2024, then plummeted by 51.88% to $1.1 million in 2025.
  • Its Payables stands at $1.1 million for Q3 2025, versus $1.9 million for Q2 2025 and $3.4 million for Q1 2025.